217 related articles for article (PubMed ID: 26980332)
21. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
22. Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study.
Hong S; Youk T; Lee SJ; Kim KM; Vajdic CM
PLoS One; 2020; 15(7):e0234927. PubMed ID: 32678818
[TBL] [Abstract][Full Text] [Related]
23. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
24. Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment.
Hwang JA; Lee JY; Kim WS; Song JS; Rho JK; Choi CM; Lee JC
Clin Lung Cancer; 2016 Nov; 17(6):573-580.e1. PubMed ID: 27378173
[TBL] [Abstract][Full Text] [Related]
25. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.
Langer C; Hirsh V
Lung Cancer; 2010 Jan; 67(1):4-11. PubMed ID: 19939491
[TBL] [Abstract][Full Text] [Related]
26. Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity?
Deberne M; Ropert S; Billemont B; Daniel C; Chapron J; Goldwasser F
BMC Cancer; 2014 Jun; 14():416. PubMed ID: 24913188
[TBL] [Abstract][Full Text] [Related]
27. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer.
Huang SM; Yang JJ; Chen HJ; Wu SP; Bai XY; Zhou Q; Tu HY; Wu YL
Oncotarget; 2017 Oct; 8(46):81369-81376. PubMed ID: 29113396
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.
Ding PN; Roberts TL; Chua W; Becker TM; Descallar J; Yip PY; Bray V
Intern Med J; 2017 Dec; 47(12):1405-1411. PubMed ID: 28742280
[TBL] [Abstract][Full Text] [Related]
30. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
[TBL] [Abstract][Full Text] [Related]
31. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Udagawa H; Niho S; Kirita K; Umemura S; Matsumoto S; Yoh K; Goto K
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1075-1082. PubMed ID: 28220258
[TBL] [Abstract][Full Text] [Related]
32. Dynamic Contrast-enhanced MR Imaging Parameters in Bone Metastases from Non-Small Cell Lung Cancer: Comparison between Lesions with and Lesions without Epidermal Growth Factor Receptor Mutation in Primary Lung Cancer.
Kim HS; Yoon YC; Kwon S; Lee JH; Ahn S; Ahn HS
Radiology; 2017 Sep; 284(3):815-823. PubMed ID: 28448232
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic Analysis of Patients with Advanced Non-small Cell Lung Cancer
in Different Genotypes].
Liu P; Wu Y; Zhou L; Qin N; Zhang Q; Zhang H; Li X; Zhang X; Lv J; Yang X; Wang J; Zhang S
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):741-750. PubMed ID: 29167003
[TBL] [Abstract][Full Text] [Related]
34. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ
Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218
[TBL] [Abstract][Full Text] [Related]
35. Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC.
Wang BX; Ou W; Mao XY; Liu Z; Wu HQ; Wang SY
Clin Neurol Neurosurg; 2017 Sep; 160():96-100. PubMed ID: 28704781
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer.
Willeumier JJ; van der Hoeven NM; Bollen L; Willems LN; Fiocco M; van der Linden YM; Dijkstra PD
Bone Joint J; 2017 Apr; 99-B(4):516-521. PubMed ID: 28385942
[TBL] [Abstract][Full Text] [Related]
37. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan.
Guan J; Chen M; Xiao N; Li L; Zhang Y; Li Q; Yang M; Liu L; Chen L
Med Oncol; 2016 Jan; 33(1):1. PubMed ID: 26589606
[TBL] [Abstract][Full Text] [Related]
38. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
[TBL] [Abstract][Full Text] [Related]
39. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
Hu XY; Zou QF; Jin C; Li WD; Chen WS; Ma L
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]